Author

B. J. Bosch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:proteomics· 2 Organism:rat· 1 Assay:structural biology· 1

Frequent Co-Authors

F. J. M. van Kuppeveld· 5 shared C. Wang· 4 shared W. Li· 4 shared D. L. Hurdiss· 3 shared I. Drulyte· 3 shared M. M. Lamers· 3 shared A. Z. Mykytyn· 2 shared B. L. Haagmans· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

F. J. M. van Kuppeveld

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein

V. Thijssen, D. L. Hurdiss, O. J. Debski-Antoniak, M. A. Spence, C. Franck, A. Norman, A. Aggarwal, N. J. Mokiem, D. A. A. van Dongen, S. W. Vermeir, M. Liu, W. Li, M. Chatziandreou, T. Donselaar, W. Du, , S. A. K. Jongkees

This paper discovers a macrocyclic peptide that inhibits SARS-CoV-2 and related sarbecoviruses by targeting a conserved site in the spike protein, offering a potential broad-spectrum antiviral.

bioRxiv · Nov 11, 2022 · PreprintBiochemistry

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants

W. Du, D. L. Hurdiss, D. Drabek, A. Z. Mykytyn, F. Kaiser, M. Gonzalez-Hernandez, D. Munoz-Santos, M. M. Lamers, R. van Haperen, W. Li, I. Drulyte, C. Wang, I. Sola, F. Armando, G. Beythien, , B. J. Bosch

bioRxiv · Feb 17, 2022 · PreprintMicrobiology

Glycosylated extracellular mucin domains protect against SARS CoV-2 infection at the respiratory surface

M. Chatterjee, L. Z. X. Huang, A. Z. Mykytyn, C. Wang, M. M. Lamers, B. Westendorp, R. W. Wubbolts, J. P. M. v. Putten, B. J. Bosch, B. Haagmans, K. Strijbis

This study shows that glycosylated mucin domains on respiratory epithelial cells restrict SARS-CoV-2 infection by reducing viral entry.

bioRxiv · Oct 29, 2021Microbiology

An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces sterile immunity and prevents transmission of SARS-CoV-2 between cats

M. A. Langereis, K. Stachura, S. Miller, A. M. Bosco-Lauth, I. C. Albulescu, A. E. Hartwig, S. M. Porter, J. Stammen-Vogelzangs, M. Mogler, F. J. M. van Kuppeveld, B. J. Bosch, P. Vermeij, A. de Groof, R. A. Bowen, R. Davis, , I. Tarpey

This paper develops a replicon-based vaccine that prevents SARS-CoV-2 infection and transmission in cats.

bioRxiv · Apr 1, 2021Microbiology

A human monoclonal antibody targeting a conserved pocket in the SARS-CoV-2 receptor-binding domain core

J. Fedry, D. L. Hurdiss, C. Wang, W. Li, G. Obal, I. Drulyte, S. C. Howes, F. J. M. van Kuppeveld, F. Förster, B. J. Bosch

This paper identifies a human monoclonal antibody, 47D11, that targets a conserved hydrophobic pocket in the SARS-CoV-2 RBD, revealing its structural basis for neutralization and potential therapeutic use.

bioRxiv · Sep 30, 2020Immunology

SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model

B. L. Haagmans, D. Noack, N. M. A. Okba, W. LI, C. Wang, T. Bestebroer, R. de Vries, S. Herfst, D. de Meulder, P. van Run, M. M. Lamers, B. Rijnders, C. Rokx, F. J. M. van Kuppeveld, F. Grosveld, , B. Rockx

This study shows that high-dose convalescent plasma or monoclonal antibodies protect hamsters from SARS-CoV-2-induced lower respiratory disease, but lower doses are ineffective.

bioRxiv · Aug 24, 2020Microbiology